GSK's Consumer Healthcare Business Posts Third-Quarter Growth

By Steve Wynne-Jones
Share this article
GSK's Consumer Healthcare Business Posts Third-Quarter Growth

The consumer healthcare division of GlaxoSmithKline, which includes brands including Panadol and Aquafresh, has posted £2.5 billion (€2.9 billion) in sales in the third quarter of the group's financial year.

This is up 3% on a pro forma basis, at constant exchange rates.

If the positive impact of the merger with the Pfizer consumer healthcare business is included, sales are up 25% for the division in the period.

Reported group sales for the period were up 11% at constant exchange rates (+6% on a pro forma basis), to £9.4 billion (€10.89 billion).

'Good Progress'

GSK has made further good progress in Q3, with sales growth across all three businesses, and we have today upgraded our full-year EPS guidance," commented Emma Walmsley, GSK chief executive.


"We also achieved a significant milestone with the completion of our new Consumer Healthcare Joint Venture with Pfizer, to create a new world leading consumer healthcare business.”

GSK anticipates 2019 adjusted EPS to be flat for the full year, at constant exchange rates.

© 2019 European Supermarket Magazine – your source for the latest retail news. Article by Stephen Wynne-Jones. Click subscribe to sign up to ESM: The European Supermarket Magazine.

Get the week's top grocery retail news

The most important stories from European grocery retail direct to your inbox every Thursday

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our terms & conditions and privacy policy. You can unsubscribe at any time.